Tradestie Institutional Equity Comparison Engine

HRMY vs AVDL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

HRMY Overall Edge

HRMY Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Harmony Biosciences Holdings, Inc. Common Stock (HRMY) driven by superior Valuation, Growth & Margin while AVDL counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, HRMY trades at 5.4x Forward P/E with 22.2% operating margin (+12.3% YoY revenue) versus AVDL at 28.8x Forward P/E and 2.5% operating margin (+54.9% YoY). In options structure, HRMY sits in CONSOLIDATION (11th %ile IV; Dealer Gamma Walls on Pro) against AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner HRMY
HRMY 5.4x vs AVDL 28.8x Fwd P/E
Growth & Margin Winner HRMY
Op Margin 22.2% vs 2.5% ยท YoY +12.3% vs +54.9%
Momentum & Technical Winner AVDL
1Y -2.2% vs +138.1% ยท 52W Pos 38% vs 89%
Options & Structure Winner AVDL
CONSOLIDATION (11th %ile IV) vs UNCLASSIFIED (<1st %ile IV)
HRMY NASDAQ
Harmony Biosciences Holdings, Inc. Common Stock
Pharmaceutical Preparations
$32.59
-1.18% 1D
Market Cap $1.9B
1M Return -9.55%
1Y Return -2.16%
Forward P/E 5.4x
Unified AI Score
67.1 / 100 BUY
Tech 80.0 Fund 74.0 Flow 70.0 Mom 70.0
AVDL NASDAQ
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
1M Return +0.65%
1Y Return +138.06%
Forward P/E 28.8x
Unified AI Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: HRMY -2.16% AVDL +138.06% Spread: +16.17 pp (HRMY Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
HRMY TTM Op. Margin: 22.2% AVDL TTM Op. Margin: 2.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HRMY vs AVDL. Trailing 12-month operating profitability (HRMY 22.2% vs AVDL 2.5%) and valuation multiples (HRMY 5.4x vs AVDL 28.8x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: HRMY (6) vs AVDL (4)
Institutional Metric HRMY AVDL Criterion Row Winner
Market Capitalization Scale $1.9B $2.1B Larger Scale AVDL
Trailing P/E Ratio Valuation 10.9x 16.8x Lower Multiple HRMY
Forward P/E Ratio Valuation 5.4x 28.8x Lower Multiple HRMY
Revenue Growth (YoY) Growth +12.3% +54.9% Higher Growth AVDL
Operating Margin (TTM) Profitability 22.2% 2.5% Higher Margin HRMY
Net Profit Margin Profitability 18.1% -0.1% Higher Margin HRMY
Return on Equity (ROE) Capital Efficiency 18.7% -0.3% Higher ROE HRMY
52-Week Range Position Momentum 38% ($26โ€“$43) 89% ($6โ€“$24) Stronger Trend AVDL
Beta / 30D Volatility Risk Regime 0.55ฮฒ ยท 38% Vol 0.14ฮฒ ยท 2% Vol Lower Realized Risk AVDL
Unified Institutional Score Composite Signal 67.1 / 100 (BUY) 62.9 / 100 (BUY) Higher Composite HRMY

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full HRMY vs AVDL Buy Guide
HRMY CONSOLIDATION
114d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 11th %ile
IV Regime Compressed (<25th %ile)
Live HRMY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AVDL UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live AVDL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither HRMY nor AVDL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.